New Delhi, March 24 -- With the patent expirations for GLP-1 drugs, used for treating type 2 diabetes and obesity, major Pharma companies have released cheaper generic alternatives. These alternatives are priced at a significantly lower price as compared to the current costs.

However, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.

To ensure that strict regulation is maintained in the usage of such drugs and to ensure ethical pharmaceutical practices in the supply chain of the Drugs Controller of India has intensified its regu...